RNAM (Avidity Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RNAM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | John B Moriarty | Chief Legal Officer | D | — | — |
| 2026-02-27 | Charles Calderaro III | Chief Technical Officer | D | — | — |
| 2026-02-27 | TROY EDWARD WILSON | Director | D | — | — |
| 2026-02-27 | Simona Skerjanec | Director | D | — | — |
| 2026-02-27 | Kathleen P. Gallagher | Chief Program Officer | D | — | — |
| 2026-02-27 | Teresa McCarthy | Chief Human Resources Officer | D | — | — |
| 2026-02-27 | Steven George Hughes | Chief Medical Officer | D | — | — |
| 2026-02-27 | Michael F MacLean | Chief Financial Officer | D | — | — |
| 2026-02-27 | Eric Mosbrooker | Chief Commercial Officer | D | — | — |
| 2026-02-27 | Jean Jinsun Kim | Director | D | — | — |
| 2026-02-27 | Edward M. MD Kaye | Director | D | — | — |
| 2026-02-27 | W. Michael Flanagan | Chief Scientific Officer | D | — | — |
| 2026-02-27 | Noreen Henig | Director | D | — | — |
| 2026-02-27 | Tamar Thompson | Director | D | — | — |
| 2026-02-27 | ARTHUR A LEVIN | Director | D | — | — |
| 2026-02-27 | Sarah Boyce | President and CEO | D | — | — |
| 2026-02-27 | CARSTEN BOESS | Director | D | — | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RNAM quote page; the site-wide leaderboard is on the insider transactions hub.